FDA Approves AbbVie/AstraZeneca Fixed-Duration CLL Combo with 77% Three-Year PFS
AbbVie and AstraZeneca’s Venclexta-Calquence oral regimen received FDA approval as the first fixed-duration frontline therapy for chronic lymphocytic leukemia. The AMPLIFY Phase 3 trial showed 77% three-year progression-free survival and a 35% reduction in progression or death versus chemo-immunotherapy.
1. FDA Approval of Combination Therapy
The U.S. regulatory agency has approved the first all-oral, fixed-duration combination of venetoclax and acalabrutinib for treatment-naive chronic lymphocytic leukemia patients. This milestone establishes a new frontline option designed to deliver targeted action against B-lymphocyte overproduction with a defined treatment period.
2. AMPLIFY Phase 3 Trial Outcomes
In the AMPLIFY trial, 77% of patients receiving the venetoclax-acalabrutinib regimen remained progression-free at three years, compared with 67% for standard chemoimmunotherapy. Median progression-free survival was not reached versus 47.6 months for the control arm, and the combination reduced the risk of progression or death by 35%.
3. Commercial Potential and Stock Implications
Analysts maintain a buy consensus with an average price target of $238.47, and some have raised targets following this approval. The therapy’s time-limited dosing and strong durability data could drive uptake in one of the most common adult leukemias, potentially boosting AbbVie’s long-term oncology revenue.